Saturday 17 October 2026
Export ABT’s income statement to Excel — free account
Abbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
104.88
0.20
+0.19%
Follow ABT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
29.37 | 28.76 | 33.68 | 16.78 |
+8 more quarters Free account |
P/S ratio |
3.39 | 3.96 | 4.92 | 5.32 | |
P/FCF ratio |
20.18 | 24.25 | 29.50 | 33.73 | |
P/Operating CF |
63.48 | 136.05 | 65.80 | 83.73 | |
P/B ratio |
3.05 | 3.39 | 4.13 | 4.55 | |
Price to Tangible BV |
0.00 | 0.00 | 9.40 | 10.76 | |
EV/Sales |
3.97 | 4.56 | 5.01 | 5.44 | |
EV/EBITDA |
17.14 | 18.92 | 19.89 | 22.00 | |
EV/Operating CF |
18.67 | 21.73 | 23.22 | 26.16 | |
EV/FCF |
23.64 | 27.87 | 30.04 | 34.49 | |
Quick Ratio |
0.80 | 0.84 | 1.02 | 1.09 | |
Current Ratio |
1.38 | 1.39 | 1.58 | 1.70 | |
Net Debt/EBITDA |
9.81 | 12.45 | 1.31 | 1.83 | |
Debt/Assets |
29.86% | 30.83% | 14.91% | 15.37% | |
Debt/Equity |
0.63 | 0.65 | 0.25 | 0.25 | |
Asset Turnover |
0.48 | 0.47 | 0.53 | 0.55 | |
Operating CF/Net income |
2.68 | 1.22 | 1.87 | 1.70 | |
Capex/Depreciation |
(0.47) | (0.50) | (0.87) | (0.63) | |
Interest Coverage |
4.82 | 7.73 | 18.76 | 17.00 | |
Research and Development Expense of Revenue |
7.08% | 6.87% | 6.41% | 6.74% | |
Selling, General and Administrative Expense of Revenue |
31.96% | 33.50% | 27.31% | 26.84% | |
Intangible Assets out of Total Assets |
0.48 | 0.48 | 0.34 | 0.35 | |
Share Based Compensation of Revenue |
1.33% | 2.84% | 0.99% | 1.06% | |
Graham Net Nets |
(0.21) | (0.18) | (0.04) | (0.03) | |
Graham Number |
45.47 | 49.29 | 50.37 | 72.69 | |
Earnings Yield |
3.41% | 3.48% | 2.97% | 5.96% | |
Free Cash Flow Yield |
4.95% | 4.12% | 3.39% | 2.96% | |
Revenue per Share |
7.24 | 6.41 | 6.58 | 6.53 | |
Operating CF per Share |
1.43 | 0.75 | 1.90 | 1.60 | |
Capex per Share |
(0.29) | (0.23) | (0.40) | (0.28) | |
Free Cash Flow per Share |
1.14 | 0.53 | 1.51 | 1.32 | |
Cash per Share |
3.22 | 4.19 | 5.13 | 4.44 | |
Shareholders Equity per Share |
29.74 | 30.24 | 30.31 | 29.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
29.74 | 30.24 | 30.31 | 29.43 | |
Free Cash Flow |
1,991.00 | 916.00 | 2,626.00 | 2,291.00 | |
Working Capital |
6,703.00 | 7,131.00 | 9,500.00 | 10,257.00 | |
Capital Expenditures |
(497.00) | (399.00) | (689.00) | (496.00) | |
Net Current Asset Value |
(32,936.00) | (32,220.00) | (7,946.00) | (8,078.00) | |
EV/EBIT |
25.17 | 26.69 | 27.58 | 30.93 | |
Capex to Sales |
0.04 | 0.04 | 0.06 | 0.04 | |
Price to Operating Income |
21.50 | 23.22 | 27.09 | 30.25 | |
| Other line items | |||||
Average Receivables |
8,285.50 | 7,768.50 | 7,427.00 | 7,594.50 | |
Average Payables |
4,550.00 | 4,446.50 | 4,217.50 | 4,078.50 | |
Average Inventory |
7,134.50 | 6,814.00 | 6,341.00 | 6,760.50 | |
Average Assets |
96,607.00 | 95,938.50 | 84,063.50 | 79,268.50 | |
Average Common Equity |
51,295.50 | 50,882.50 | 50,336.00 | 45,646.00 |
Columns are period end dates